Search

Juan Wang

from Foster City, CA
Age ~52
Get Report
Also known as:
Juan Song, An Wang Ju
Phone and address:
861 Gull Ave, San Mateo, CA 94404
Related to:
Lillie Wang, 50Simon X Shang, 67
Connected to:
Aaron Wang, 36Aijie Wang, 54Ailin Y Wang, 67Aiying Wang, 63Alex F Wang, 51Alexandra Wang, 50Alfred C Wang, 47Ally H Wang, 50Amerfil M Wang, 80Andreas Wang, 28

Juan Wang Phones & Addresses

  • 861 Gull Ave, San Mateo, CA 94404
  • Foster City, CA
  • Castro Valley, CA
  • Santa Cruz, CA
  • Union City, CA
  • South San Francisco, CA
  • Fairfield, CA
  • Redwood City, CA
  • Andover, MA
  • Alameda, CA
  • Modesto, CA
  • 205 N Humboldt St, San Mateo, CA 94401

Professional Records

Lawyers & Attorneys

Juan Wang Photo 1

Juan Wang - Lawyer

View page
Specialties:
Litigation
Intellectual Property
Antitrust & Trade Law
Arbitration
ISLN:
923930430
Admitted:
2012

Resumes

Resumes

Juan Wang Photo 2

Attorney At Hua Jun & Co.

View page
Position:
Attorney at HUA JUN & CO.
Location:
Wuhan, Hubei, China
Industry:
Law Practice
Work:
HUA JUN & CO. - Wuhan, Hubei, China since Apr 2013
Attorney
Law Office of Zhiyu Hu - Edison, New Jersey Mar 2012 - Dec 2012
Paralegal
29th Circuit Court in Michigan - Michigan May 2011 - Aug 2011
Intern as a law clerk
Deheng Law Firm - Wuhan City, China Jun 2006 - Aug 2009
Attorney
Education:
Michigan State University College of Law 2010 - 2011
Master of Laws (LL.M.) Wuhan University Law School, China 2002 - 2005
Ph.D in Law, Private International Law
Interests:
sports,music, travel
Juan Wang Photo 3

Software Engineer

View page
Location:
19981 Garnett Ct, Saratoga, CA 95070
Industry:
Computer Software
Work:
Facebook
Software Engineer
Littlelights.ai Startup Jul 2017 - Sep 2017
Android Developer Internship
Education:
Santa Clara University 2016 - 2018
Masters
Skills:
Project Management
Engineering
Management
Contract Management
Android Development
Web Development
Juan Wang Photo 4

Cosmetics

View page
Industry:
Cosmetics
Work:

Cosmetics
Juan Wang Photo 5

Juan Wang

View page
Juan Wang Photo 6

Juan Wang

View page
Juan Wang Photo 7

Juan Wang

View page
Juan Wang Photo 8

Juan Wang

View page
Juan Wang Photo 9

Juan Wang

View page

Publications

Us Patents

[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms And Methods Related Thereto

View page
US Patent:
20090156620, Jun 18, 2009
Filed:
Nov 5, 2008
Appl. No.:
12/265699
Inventors:
Emma Sharp - Cambridgeshire, GB
Louisa Jane Quegan - Cambridgeshire, GB
Anjali Pandey - Fremont CA, US
Juan Wang - Foster City CA, US
Matthew Nieder - San Francisco CA, US
Wolin Huang - Foster City CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07D 409/12
A61K 31/517
C12N 5/06
A61P 9/00
A61P 7/00
US Classification:
51426624, 544285, 435375
Abstract:
The present invention provides novel sulfonylurea salts of a salt of formula (I)

Device, System And Method For Automatic Data Solidification

View page
US Patent:
20090185469, Jul 23, 2009
Filed:
Jan 18, 2008
Appl. No.:
12/016311
Inventors:
Juan Wang - San Jose CA, US
International Classification:
G11B 7/28
US Classification:
369 85
Abstract:
A device, system and method is invented to solidify data from temporary storage media to long term storage media without intervention of computer. Those who can not access computer are enabled to use digital recording apparatus, such as digital camera. The operation of the device is restricted in order to increase the ease of use, and to provide the core function. The core function is to read data from temporary storage media, such as various memory cards, and write the data to long term storage media, such as user-writeable CD or DVD. The device features a minimal set of hardware components for accomplishing this function, such as a simplified user interface, an embedded processor, a data reading channel, and a data solidification channel. A data play mode can also be optionally implemented for the user to check the solidified data.

Solid Composition For Controlled Release Of Ionizable Active Agents With Poor Aqueous Solubility At Low Ph And Methods Of Use Thereof

View page
US Patent:
20100151019, Jun 17, 2010
Filed:
Nov 13, 2009
Appl. No.:
12/618511
Inventors:
Chandir Ramani - Brampton, CA
Juan Wang - Foster City CA, US
Anil Kane - Mississauga, CA
Kwok Chow - Mississauga, CA
Joe Lambing - South San Francisco CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 9/22
A61K 31/517
A61P 9/00
A61P 7/02
US Classification:
424465, 51426624
Abstract:
A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37 C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.

Crystalline Forms Of A Factor Xa Inhibitor

View page
US Patent:
20110160250, Jun 30, 2011
Filed:
Dec 16, 2010
Appl. No.:
12/970818
Inventors:
Anjali Pandey - Fremont CA, US
Juan Wang - Foster City CA, US
Joseph Lambing - Burlingame CA, US
International Classification:
A61K 31/4439
C07D 409/14
C12N 9/99
A61P 9/10
A61P 7/02
US Classification:
514341, 5462751, 435184
Abstract:
The present invention provides crystalline forms of a mesylate salt of the compound 5-chloro-N-((1-(4-(2-oxopyridin-1(2H)-yl)phenyl)-1H-imidazol-4-yl)methyl)thiophene-2-carboxamide and pharmaceutical compositions and methods thereof.

[4-(6-Fluoro-7-Methylamino-2,4-Dioxo-1,4-Dihydro-2H-Quinazolin-3-Yl)-Phenyl]-5-Chloro-Thiophen-2-Yl-Sulfonylurea Salts, Forms And Methods Related Thereto

View page
US Patent:
20120129876, May 24, 2012
Filed:
Jun 22, 2011
Appl. No.:
13/166763
Inventors:
Emma Sharp - Cambridgeshire, GB
Louisa Jane Quegan - Cambridgeshire, GB
Anjali Pandey - Fremont CA, US
Juan Wang - Foster City CA, US
Matthew Nieder - San Francisco CA, US
Wolin Huang - Foster City CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 31/517
A61P 9/10
A61P 7/02
C07D 409/12
A01N 1/02
US Classification:
51426624, 544285, 435 2
Abstract:
The present invention provides novel sulfonylurea salts of a salt of formula (I)

Dosage Forms Of Elinogrel And Methods Of Injectable Administration Thereof

View page
US Patent:
20130131089, May 23, 2013
Filed:
May 2, 2011
Appl. No.:
13/695428
Inventors:
Hui Li - Sammamish WA, US
Juan Wang - Foster City CA, US
Joe Lambing - Burlingame CA, US
Harry Tiemessen - Weil am Rhein, DE
Assignee:
Portola Phamaceuticals Inc. - South San Francisco CA
International Classification:
A61K 9/00
US Classification:
51426624
Abstract:
The present invention is concerned with a liquid delivery form of Elinogrel for the treatment of thrombosis which is notable for its improved dosage properties and stability. The dosage form is a liquid or a lyophilized form which is reconstituted for an injectable formulation comprising: a) at least about 3 mg/ml or up to about 15 mg/ml Elinogrel or a pharmaceutically acceptable salt thereof (post reconstitution or in liquid form), and b) at least one pharmaceutically acceptable excipient. Further aspects of the present invention concern the preparation and use of such a formulation.

Pharmaceutical Composition And Dosage Forms Of Elinogrel And Methods Of Use Thereof

View page
US Patent:
20130165459, Jun 27, 2013
Filed:
Jan 12, 2011
Appl. No.:
13/521906
Inventors:
Juan Wang - Foster City CA, US
Chandir Ramani - Brampton, CA
Joe Lambing - South San Francisco CA, US
Christine Ye - South San Francisco CA, US
Elizabeth Vadas - Dorval, CA
Julian Taillemite - Huningue, FR
Marie-Pierre Filliot - Geispitzen, FR
Dieter Becker - Freiburg, DE
Assignee:
NORVARTIS PHARMA AG - Basel
PORTOLA PHARMACEUTICALS, INC. - San Francisco CA
International Classification:
A61K 45/06
A61K 31/64
US Classification:
51426624
Abstract:
The present invention is concerned with a solid delivery form of elinogrel for the treatment of thrombosis which is notable for its multi-pH dissolution, immediate release and improved pharmacokinetic properties and stability in storage. The delivery and dosage form is a solid, oral formulation comprising: a) at least about 15% by weight elinogrel or a pharmaceutically acceptable salt thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. A further aspect of the present invention concerns the preparation and use of such a formulation.

Solid Composition For Controlled Release Of Ionizable Active Agents With Poor Aqueous Solubility At Low Ph And Methods Of Use Thereof

View page
US Patent:
20130172374, Jul 4, 2013
Filed:
Oct 1, 2012
Appl. No.:
13/633055
Inventors:
Juan Wang - Foster City CA, US
Anil Kane - Mississauga, CA
Kwok Chow - Mississauga, CA
Joe Lambing - South San Francisco CA, US
Assignee:
Portola Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
A61K 47/38
A61K 47/10
A61K 9/00
US Classification:
51426624, 514781, 5147723, 514770, 514769, 514784, 264109
Abstract:
A novel solid composition and methods for making and using the solid composition are provided. The solid composition comprises: (a) at least one active agent with a solubility of less than about 0.3 mg/ml in an aqueous solution with a pH of at most about 6.8 at a temperature of about 37 C.; and (b) a hydrophilic polymer matrix composition comprising: i) a hydrophilic polymer selected from the group consisting of METHOCEL™, POLYOX™ WSR 1105 and combinations thereof; and optionally ii) a hydrophobic polymer selected from the group consisting of Ethocel 20 premium; and (c) an alkalizer selected from the group consisting of calcium carbonate, magnesium oxide heavy and sodium bicarbonate; wherein the composition provides at least about 70% release of the active between about 7 to about 12 hours following oral administration.
Control profile
Juan Wang from Foster City, CA, age ~52 Get Report